Explain how the hypothesis below came up based on the initial observations (see below).
Hypothesis: The recombinant-based assay for HCV will detect HCV antibodies in blood samples of people with hepatitis C or who are carriers of HCV, but not in non-HCV individuals.
I. Hepatitis is a general category of liver diseases. Several different viral agents have been found to infect the liver and cause inflammation and damage.
II. In the 1940s, researchers identified two forms of viral hepatitis. Infectious hepatitis, or hepatitis A, is transmitted by contact with feces from infected individuals. Serum hepatitis, or hepatitis B, is transmitted through the blood and other body fluids. The hepatitis B virus was isolated in the 1960s and the hepatitis A virus was isolated in the 1970s.
III. Following the isolation of these two viruses, assays were developed in order to identify individuals infected with hepatitis A or hepatitis B viruses.
IV. A form of hepatitis occurs in patients that test negative for hepatitis A or B. This form of hepatitis, initially called non-A, non-B hepatitis (NANBH) but now referred to as hepatitis C, represented greater than 90% of transfusion-associated hepatitis.
V. Hepatitis C causes chronic disease which can lead to cirrhosis of the liver and liver cancer.
VI. A recombinant-based assay for the hepatitis C virus (HCV) has been developed, using RNA isolated from the hepatitis C virus.